Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Below is a presentation of our financial results comparing FY 2024 to FY 2023, and are based on our results published in our Form 10-K filed with the SEC on April 15, 2025. Net income (loss) ...

AXS-12, known as reboxetine back when it was available as an antidepressant in the United States, may decrease cataplexy ...

Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s ...

A genetically engineered pig kidney helped Towana Looney enjoy 130 days without the need for dialysis before the organ was ...

Gene therapy for cystic fibrosis is advancing fast. Explore key biotech players, clinical progress, and its potential to ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.

Proposals that focus on one or more of the following areas will be prioritized 1: The USDA will provide funding to eligible ...

Durham-based Atsena Therapeutics has raised $150 million to advance gene therapies for preventing or reversing types of ...

Liquidia's collaboration with Sandoz and development of new products like L606 show promise. Learn why LQDA stock is a Hold.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...